PARADIGM-HF and PARAGON-HF: Redefining HFrEF and HFpEF
Video navigation menu
- Neprilysin and heart failure 00:57
- Outcomes of the PARADIGM-HF trial in HFrEF patients 02:56
- Outcomes of the PARAGON-HF trial in HFpEF patients 06:04
- HFrEF definition should be EF <50% 10:04
- Conclusions from PARADIGM-HF and PARAGON-HF trials 11:06
Do you agree with the proposed HFrEF definition of EF <50%?
- No, there is a subgroup of HFmrEF patients (EF 40-49%)
This educational video is the first part of a serie called "Reviewing HFpEF: Lessons and implications from PARAGON-HF" that is aimed to give cardiologists and other health care professionals involved in the management of heart failure a well-balanced expert view on findings derived from the PARAGON-HF trial.
Milton Packer, MD, is an internationally recognized clinical investigator in the field of heart failure. He spent most of this career in New York City, where he was the Dickinson Richards Professor and Chief of the Division of CIrculatory Physiology at Columbia University. From 2004-2015 he was Professor and Chair of the Department of Clinical Sciences at the University of Texas Southwestern Medical Center at Dallas. Dr. Packer is currently the Distinguished Scholar in Cardiovascular Science at Baylor University Medical Center, part of Baylor Scott & White Health.
This recording was independently developed under auspices of PACE-cme. The views expressed in this recording are those of the individual presenter and do not necessarily reflect the views of PACE-cme.
Funding for this educational program was provided by an unrestricted educational grant from Novartis